Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus XELOX first-line study in advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400089954Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Renji Hospital. Primary endpoint: objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400089954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089954.